moomoo ID:NaN
Log Out
Log in to access Online Inquiry

快讯:中药股继续活跃 精华制药4连板
News flash: traditional Chinese medicine unit continues to be active essence pharmaceutical 4 continuous board

新浪財經綜合 ·  {{timeTz}}


December 29 news, traditional Chinese medicine stocks continue to be active, as of press time, essence Pharmaceutical 4-board, Watson Pharmaceutical rose, Tai long Pharmaceutical, Yabao Pharmaceutical, Foci Pharmaceutical followed.


On the news side, recently, the prices of proprietary Chinese medicines in several well-known domestic pharmaceutical companies have increased by 10% to 20%, including some common varieties. Affected by this, the Chinese medicine plate continues to heat up recently. Industry insiders said that the rise in the price of proprietary Chinese medicine is mainly due to the rise in the price of traditional Chinese medicine. Brokerage analysis believes that under the policy support and the catalysis of price increase, traditional Chinese medicine enterprises with low valuation and strong brand influence have been paid attention to. In the past two years, a number of incentive policies have been issued, the traditional Chinese medicine industry has ushered in new opportunities for development, and enterprise management is expected to improve.

This page is machine-translated. Moomoo tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.